RCS - Angle PLC - Parsortix enriched CTC & ctDNA in NSCLC patients

AngleAnnouncement

11/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241111:nRSK6014La&default-theme=true

RNS Number : 6014L  Angle PLC  11 November 2024

 For immediate release  11 November 2024

 

ANGLE plc ("the Company")

 

DNA analysis of Parsortix-enriched CTCs and ctDNA provides complementary
information in NSCLC patients treated with AstraZeneca's osimertinib

 

The addition of CTC-DNA analysis to clinical trials could identify patients
developing treatment resistance prior to disease progression

 

CTC analysis identifies druggable targets which could be used to inform
combined targeted treatment

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the publication of
research investigating the dual analysis of CTCs and circulating tumour DNA
(ctDNA) in non-small cell lung cancer (NSCLC), undertaken by the National and
Kapodistrian University of Athens.

 

Researchers used the Parsortix(®) system to isolate and harvest CTCs from 30
patients with EGFR-mutated NSCLC that were undergoing treatment with
osimertinib (TAGRISSO: AstraZeneca). Osimertinib is an EGFR inhibitor with
annual revenues of c. US$6.7 billion, growing at c. 16% per annum. Both CTCs
and ctDNA were analysed using a range of molecular techniques which enabled
the identification of mutations, methylation, gene expression and
amplification.

 

The study provides further evidence that complementary information can be
obtained through dual analysis of CTC-DNA and ctDNA. Using the dual analysis
technique, at disease progression an increased number of patients were
identified with the EGFR T790M resistance mutation and DNA methylation,
compared to analysis of either analyte alone. Dual analysis of these liquid
biopsy analytes enables longitudinal monitoring of patients throughout
clinical trials and may enable early identification of non-responders and
identify patients becoming resistant to treatment before disease progression.

 

Additional analysis of CTCs identified druggable molecular markers, such as
HER2, PD-L1, PIM-1 and AXL, at study baseline and at disease progression,
providing information on the potential benefits of combined targeted
treatment, and possible suitable therapies for those patients whose cancer
progresses due to resistance to osimertinib. This adds to the body of evidence
supporting ANGLE's large pharma strategy, highlighting the potential to aid in
the stratification of patients that may benefit from alternative/combinatorial
therapies being investigated in clinical trials.

 

Chief Scientific Officer, Karen Miller, commented:

"This study supports our pharma services business by demonstrating how dual
molecular analysis of Parsortix-enriched CTCs and ctDNA could improve patient
stratification in clinical trials investigating new targeted therapies or new
therapy combinations. This approach could ultimately lead to the development
of more targeted drugs or better drug combinations that could result in better
outcomes for patients, all of which may require a Parsortix-based companion
diagnostic to support regulatory approval."

 

The research, published as a peer-reviewed publication in the journal
Frontiers in Oncology, is available online at
https://angleplc.com/resources/publications/.

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer. The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood. The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays. The end user
is responsible for the validation of any downstream assay. The standalone
device, as indicated, does not identify, enumerate or characterize CTCs and
cannot be used to make any diagnostic/prognostic claims for CTCs, including
monitoring indications or as an aid in any disease management and/or treatment
decisions.

 

All results reported in this announcement and any other products and services
are for research use only and not for use in diagnostic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMZMGMNRKGDZM